Silo Pharma Inc. has announced a significant step in the development of its novel intranasal PTSD therapy, SPC-15. The biopharmaceutical company, focused on pioneering therapeutics and drug delivery systems, has partnered with Veloxity Labs, LLC for a bioanalytical study necessary for the investigational new drug $(IND.AU)$-enabling process. This collaboration aims to support the ongoing GLP-compliant toxicology and toxicokinetics study of SPC-15. Silo Pharma plans to initiate the FDA IND process later in 2025, with hopes of progressing to a first-in-human Phase 1 clinical trial following approval. The CEO, Eric Weisblum, highlighted the importance of Veloxity Labs in providing fast and precise data crucial for advancing SPC-15 into clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.